REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Acepodia,Inc (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Acepodia,Inc Profile Updated: November 01, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Acepodia,Inc is engaged in the research and development of immunotherapy of new generation cell drugs, targeting solid tumors and blood cancers. The company's main products include new cell drug preparations. The company was established in 2017 and is headquartered in New Taipei City, Taiwan.

Headquarters
17F.-12, No. 99, Sec. 1, Xintai 5Th Rd., Xizhi Dist
New Taipei City; New Taipei City;

Contact Details: Purchase the Acepodia,Inc report to view the information.

Website: http://www.acepodia.com

Basic Information
Outstanding Shares:
Purchase the Acepodia,Inc report to view the information.
Financial Auditors:
Purchase the Acepodia,Inc report to view the information.
Incorporation Date:
February 15, 2017
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
36.95%
Purchase this report to view the information.
3.99%
Purchase this report to view the information.
3.51%
Purchase this report to view the information.
Purchase this report to view the information.
Subsidiaries
Acepodia Biotech,Inc. (United States)
100%
育世博生物科技股份有限公司
100%
Company Performance
Financial values in the chart are available after Acepodia,Inc report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Operating profit (EBIT)
-56.46%▼
EBITDA
53.04%▲
Net Profit (Loss) for the Period
70.69%▲
Total assets
-0.32%▼
Total equity
-1.07%▼
Return on Equity (ROE)
6.54%▲
Quick Ratio
-15.07%▼
Cash Ratio
-15.21%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo